1285 related articles for article (PubMed ID: 25550361)
21. Defining Acute Myeloid Leukemia Ontogeny in Older Patients.
Melody M; Kuykendall A; Sallman D; Al Ali N; Zhang L; Talati C; Padron E; Sweet K; Extermann M; List A; Lancet J; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):312-315. PubMed ID: 32139296
[TBL] [Abstract][Full Text] [Related]
22. Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
Saygin C; Hirsch C; Przychodzen B; Sekeres MA; Hamilton BK; Kalaycio M; Carraway HE; Gerds AT; Mukherjee S; Nazha A; Sobecks R; Goebel C; Abounader D; Maciejewski JP; Advani AS
Blood Cancer J; 2018 Jan; 8(1):4. PubMed ID: 29321554
[TBL] [Abstract][Full Text] [Related]
23. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
Gardin C; Pautas C; Fournier E; Itzykson R; Lemasle E; Bourhis JH; Adès L; Marolleau JP; Malfuson JV; Gastaud L; Raffoux E; Lambert J; Braun T; Thomas X; Chantepie S; Cluzeau T; de Botton S; Berthon C; Boissel N; Duployez N; Terré C; Peffault de Latour R; Michallet M; Celli-Lebras K; Preudhomme C; Dombret H
Blood Adv; 2020 May; 4(9):1942-1949. PubMed ID: 32380535
[TBL] [Abstract][Full Text] [Related]
24. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW;
Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327
[TBL] [Abstract][Full Text] [Related]
25. Spliceosome mutations in hematopoietic malignancies.
Hahn CN; Scott HS
Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
[TBL] [Abstract][Full Text] [Related]
26. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
27. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
[TBL] [Abstract][Full Text] [Related]
28. [Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].
Zhu C; Ma Y; Xu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):873-8. PubMed ID: 24989313
[TBL] [Abstract][Full Text] [Related]
29. SF3B1 mutation is a rare event in Chinese patients with acute and chronic myeloid leukemia.
Yang J; Qian J; Yao DM; Qian SX; Qian W; Lin J; Xiao GF; Wang CZ; Deng ZQ; Ma JC; Chen XX
Clin Biochem; 2013 May; 46(7-8):701-3. PubMed ID: 23395771
[TBL] [Abstract][Full Text] [Related]
30. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
[TBL] [Abstract][Full Text] [Related]
31. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
32. Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia.
Gao Y; Jia M; Mao Y; Cai H; Jiang X; Cao X; Zhou D; Li J
Am J Clin Pathol; 2022 May; 157(5):691-700. PubMed ID: 34664628
[TBL] [Abstract][Full Text] [Related]
33. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Gillis NK; Ball M; Zhang Q; Ma Z; Zhao Y; Yoder SJ; Balasis ME; Mesa TE; Sallman DA; Lancet JE; Komrokji RS; List AF; McLeod HL; Alsina M; Baz R; Shain KH; Rollison DE; Padron E
Lancet Oncol; 2017 Jan; 18(1):112-121. PubMed ID: 27927582
[TBL] [Abstract][Full Text] [Related]
34. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
Lachowiez CA; Loghavi S; Furudate K; Montalban-Bravo G; Maiti A; Kadia T; Daver N; Borthakur G; Pemmaraju N; Sasaki K; Alvarado Y; Yilmaz M; Short NJ; Chien K; Ohanian M; Pierce S; Patel KP; Jabbour E; Ravandi F; Kantarjian HM; Garcia-Manero G; Takahashi K; Konopleva MY; DiNardo CD
Blood Adv; 2021 Apr; 5(8):2173-2183. PubMed ID: 33885753
[TBL] [Abstract][Full Text] [Related]
35. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
37. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.
Patnaik MM; Padron E; LaBorde RR; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Al-kali A; Pardanani A; Ali NA; Komrokji RS; Tefferi A
Leukemia; 2013 Jul; 27(7):1504-10. PubMed ID: 23531518
[TBL] [Abstract][Full Text] [Related]
38. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.
Hahn CN; Venugopal P; Scott HS; Hiwase DK
Immunol Rev; 2015 Jan; 263(1):257-78. PubMed ID: 25510282
[TBL] [Abstract][Full Text] [Related]
39. Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors.
Zorzan E; Hanssens K; Giantin M; Dacasto M; Dubreuil P
PLoS One; 2015; 10(11):e0142450. PubMed ID: 26562302
[TBL] [Abstract][Full Text] [Related]
40. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
Bamopoulos SA; Batcha AMN; Jurinovic V; Rothenberg-Thurley M; Janke H; Ksienzyk B; Philippou-Massier J; Graf A; Krebs S; Blum H; Schneider S; Konstandin N; Sauerland MC; Görlich D; Berdel WE; Woermann BJ; Bohlander SK; Canzar S; Mansmann U; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T
Leukemia; 2020 Oct; 34(10):2621-2634. PubMed ID: 32358566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
